Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019

Published: July 2014
No. of Pages: 232
   

Insulin Glargine, Insulin Lispro, and Insulin Aspart Will Go Off-Patent in 2014-2015 – A Prime Target For Human Insulin Drug Makers

Several initiatives and healthcare reforms have been developed in order to support the adoption of human insulin among diabetic population as diabetes will be the seventh leading cause of mortality by 2030. WHO and IDF began joint initiative to reduce the impact of diabetes and related chronic conditions on the health of children and adults worldwide. Apart from this, the U.S. government has now started taking various initiatives to boost its biosimilars market. In 2013, Obama’s administration sponsored a budget of $4.5 billion, an increase of 17% over 2012, to FDA in order to support the review of generics and biosimilars. The funding would mostly come from user fees paid by drug makers. More than $364 million will be allocated to support generic drug activities and development of biosimilars, out of which $20 million will be allocated to the FDA for biosimilars.

Modern human insulin accounted for the largest share-84%- of global human insulin market. Premixed modern human insulin and long acting human insulin are estimated to grow at a brisk pace over the next five years. The high growth in these segments can be attributed to the growing demand of Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency and effectiveness as compared to other synthetic insulin, animal insulin, and other human insulin.

New technologies such as safety pen needles and infusion pumps have emerged as efficient mode of delivery for human insulin.Pen needles offer significant benefits to the healthcare sector. The usage of easy to fit needles is rising due to the convenience offered by them. These needles are easy to attach, remove, and dispose, thus they can be easily used by patients with manual dexterity problems, and visual impairment. Diabetes educators and clinicians across the world recommend the usage of needles with shorter lengths and higher gauge sizes for convenience and to minimize pain. Owing to these factors, technological advancement is expected to be a major revenue pocket for the human insulin market in the coming years.

Countries such as China, India, Japan, and Korea will also offer potential growth opportunities to human insulin market.Of all the countries, China is estimated to be the fastest growing market for human insulin market. Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative markets for human insulin market.

Above all, most of the early biologic human insulin lost their patent protection in the first half of the 20th century, while many of the current best-selling drugs such as insulin glargine, insulin as part, and insulin lispro are all set to lose their patent protection in the coming years. This creates new opportunities for biosimilar drugs which is estimated to grow at a CAGR of 35% from 2014-2019.

The grey area while estimating the market size is the variable price of human insulin across the globe as it differs widely across each country.

From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles.

The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), and porter’s five forces analysis at global level. The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of human insulin market (Biosimilars of human insulin, long acting human insulin, and premixed human insulin), high-growth regions (Asia-Pacific), and the initiatives of their respective governments.

The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the human insulin market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019

Table of Content

1 Introduction
1.1 Objectives of the Study
1.2 Report Description
1.3 Market Scope
1.4 Market Covered
1.5 Research Methodology
1.5.1 Market Size Estimation
1.5.2 Forecasting Model
1.6 Key Data From Secondary & Primary Sources
1.7 Assumptions

2 Executive Summary

3 Premium Insights
3.1 Market Overview
3.2 Market Snapshot
3.3 Market, By Type
3.4 Market, By Brand
3.5 Market, By Geography
3.6 Human Insulin Market, By Region

4 Market Overview
4.1 Introduction
4.2 History
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Increasing Diabetic Population
4.4.1.2 Rapidly Growing Aging Population
4.4.1.3 Growing Prevalence of Lifestyle-Related Disorders Such As Obesity
4.4.1.4 Biologics Going off-Patent to Boost the Market
4.4.1.5 R&D Initiatives Aimed At Developing New Products
4.4.1.6 Favorable Government Initiatives to Drive the Human Insulin Market
4.4.1.7 Growing Demand for Biosimilar Drugs Due to their Cost-Effectiveness
4.4.1.8 Growing Demand for Insulin Analogs
4.4.1.9 Technological Advancements to Propel the Human Insulin Market
4.4.2 Restraints
4.4.2.1 High Manufacturing Complexities and Cost of Production to Hinder the Market Growth
4.4.2.2 Stringent Regulatory Requirements to Restrict the Growth of the Human Insulin Market
4.4.3 Opportunities
4.4.3.1 Emerging Countries Present Significant Growth Opportunities
4.4.3.2 Pipeline Products offer Huge Growth Opportunities
4.4.4 Challenges
4.4.4.1 Requirement of Complex Infrastructure for Manufacturing and Extensive Clinical Trials for Approvals
4.5 Winning Imperatives
4.5.1 Collaborations and Agreements to Help Players Gain A Competitive Edge
4.6 Burning Issues
4.6.1 Product Recalls

5 Market Share Analysis
5.1 Market Share Analysis
5.1.1 Global Market Share Analysis
5.1.2 Market Share Analysis, By Geography
5.1.2.1 North America
5.1.2.2 Europe
5.1.2.3 Asia-Pacific
5.1.2.4 ROW

6 Pipeline Analysis
6.1 Pipeline Analysis

7 Human Insulin Market,By Type
7.1 Introduction
7.2 Traditional Human Insulin
7.2.1 Short-Acting Insulin
7.2.2 Intermediate-Acting Insulin
7.2.3 Premixed Traditional Human Insulin
7.3 Modern Human Insulin
7.3.1 Rapid-Acting Insulin
7.3.2 Long-Acting Insulin
7.3.3 Premixed Modern Human Insulin

8 Human Insulin Market,By Brand
8.1 Introduction
8.2 Traditional Human Insulin Market, By Brand
8.2.1 Humulin
8.2.2 Actrapid, Mixtard, & Insulatard
8.2.3 Humulin
8.3 Modern Human Insulin Market, By Brand
8.3.1 Lantus
8.3.2 Novorapid/Novolog
8.3.3 Humalog
8.3.4 Levemir
8.3.5 Novomix
8.3.6 Apidra
8.3.7 Tresiba

9 Human Insulin Market,By Geography
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Roe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Korea, Australia, and Roa
9.5 ROW
9.5.1 Middle East
9.5.2 Latin America
9.5.3 Africa

10 Competitive Landscpe
10.1 Introduction
10.2 New Product Approvals
10.3 Collaborations, Agreements, and Joint Ventures
10.4 Other Developments

11 Company Profiles
11.1 Novo Nordisk - Overview
11.2 Eli Lilly - Overview
11.3 Sanofi - Overview
11.4 Biocon - Overview
11.5 Julphar - Overview

List of Tables

Table 1 Global Market Size, By Product,2012–2019 ($Million)
Table 2 Global Market Size,2014-2019 (Tmu)
Table 3 Global Traditional Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 4Global Traditional Human Insulin Market Size, By Region,2012–2019 ($Million)
Table 5 Global Short-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 6 Global Intermediate-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 7 Global Premixed Traditional Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 8 Global Modern Insulin Market Size, By Type, 2012–2019 ($Million)
Table 9 Global Modern Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 10 Global Rapid-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 11 Global Long-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 12 Global Premixed Modern Insulin Market Size, By Region, 2012–2019 ($Million)
Table 13 Global Traditional Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 14 Global Humulin Market Size, By Region, 2012–2019 ($Million)
Table 15 Global Actrapid, Mixtard, & Insulatard Market Size, By Region, 2012–2019 ($Million)
Table 16 Global Insuman Market Size,By Region, 2012–2019 ($Million)
Table 17 Global Modern Human Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 18 Global Lantus Market Size, By Region, 2012–2019 ($Million)
Table 19 Global Novorapid/Novolog Market Size, By Region, 2012–2019 ($Million)
Table 20 Global Humalog Market Size, By Region, 2012–2019 ($Million)
Table 21 Global Levemir Market Size, By Region, 2012–2019 ($Million)
Table 22 Global Novomix Market Size, By Region, 2012–2019 ($Million)
Table 23 Global Apidra Market Size, By Region, 2012–2019 ($Million)
Table 24 Global Tresiba Market Size, By Region, 2012–2019 ($Million)
Table 25 Market Size, By Region, 2012–2019 ($Million)
Table 26 Global Market Size, By Country, 2012–2019 ($Million)
Table 27 Long-Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 28 Rapid-Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 29 Premixed Modern Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 30 Short-Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 31 Intermediate-Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 32 Premixed Traditional Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 33 North America: Diabetes Prevalence Rate
Table 34 North America: off-Patent Human Insulin Products
Table 35 North America: Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 36 North America: Traditional Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 37 North America: Modern Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 38 North America: Traditional Human Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 39 North America: Traditional Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 40 North America: Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 41 North America: Modern Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 42 U.S.: Market Size, By Type, 2012–2019 ($Million)
Table 43 Canada: Market Size, By Type, 2012–2019 ($Million)
Table 44 North America: Short Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 45 North America: Intermediate-Acting Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 46 North America: Premixed Traditional Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 47 North America: Long-Acting Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 48 North America: Rapid-Acting Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 49 North America: Premixed Modern Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 50 Europe: Diabetes Prevalence Rate
Table 51 Europe : Off-Patent Human Insulin Products
Table 52 Europe: Market Size, By Type, 2012–2019 ($Million)
Table 53 Europe: Traditional Market Size, By Type, 2012–2019 ($Million)
Table 54 Europe: Modern Market Size, By Type, 2012–2019 ($Million)
Table 55 Europe: Traditional Human Insulin Market Size, ByBrand, 2012–2019 ($Million)
Table 56 Europe: Modern Human Insulin Market Size, ByBrand, 2012–2019 ($Million)
Table 57 Europe: Traditional Human Insulin Market Size, ByBrand, 2012–2019 ($Million)
Table 58 Europe: Modern Human Insulin Market Size, ByBrand, 2012–2019 ($Million)
Table 59 Germany: Market Size, By Type, 2012–2019 ($Million)
Table 60 France: Market Size, By Type, 2012-2019 ($Million)
Table 61 U.K.: Market Size, By Type, 2012–2019 ($Million)
Table 62 Italy: Market Size, By Type, 2012–2019 ($Million)
Table 63 Spain: Market Size, By Type, 2012–2019 ($Million)
Table 64 Roe: Market Size, By Type, 2012–2019 ($Million)
Table 65 Europe: Short-Acting Traditional Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 66 Europe: Intermediate-Acting Traditional Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 67 Europe: Premixed Traditional Human Insulin Market Size, By Country/Region, 2012-2019 ($Million)
Table 68 Europe: Long-Acting Modern Human Insulin Market Size, By Country/Region, 2012–2019 ($Million)
Table 69 Europe: Rapid-Acting Modern Human Insulin Market Size Size, By Country/Region, 2012–2019 ($Million)
Table 70 Europe: Premixed Modern Human Insulin Market Size, By Country/Region, 2012–2019 ($Million)
Table 71 Asia-Pacific: Diabetes Prevalence Rate
Table 72 Asia-Pacific: Off-Patent Human Insulin Products
Table 73 Asia-Pacific: Market Size, By Type, 2012–2019 ($Million)
Table 74 Asia-Pacific: Traditional Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 75 Asia-Pacific: Modern Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 76 Asia-Pacific: Traditional Human Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 77 Asia-Pacific: Modern Human Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 78 Asia-Pacific: Traditional Human Insulin Market Size, ByCountry, 2012-2019 ($Million)
Table 79 Asia-Pacific: Modern Human Insulin Market Size, ByCountry, 2012-2019 ($Million)
Table 80 China: Market Size, By Type, 2012–2019 ($Million)
Table 81 China: Market Size, By Type, 2012–2019 ($Million)
Table 82 Japan: Market Size, By Type, 2012-2019 ($Million)
Table 83 Australia: Market Size, By Type, 2012-2019 ($Million)
Table 84 Korea: Market Size, By Type, 2012–2019 ($Million)
Table 85 Roa: Market Size, By Type, 2012–2019 ($Million)
Table 86 Asia-Pacific: Short-Acting Traditional Human Insulin Market Size, By Country, 2012-2019 ($Million)
Table 87 Asia-Pacific: Short-Acting Traditional Human Insulin Market Size, By Country, 2012-2019 ($Million)
Table 88 Asia-Pacific: Premixed Traditional Human Insulin Market Size, By Country, 2012–2019 ($Million)
Table 89 Asia-Pacific: Long-Acting Modern Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 90 Asia-Pacific: Rapid-Acting Modern Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 91 Asia-Pacific: Premixed Modern Human Insulin Market Size, ByCountry, 2012–2019 ($Million)
Table 92 ROW: Diabetes Prevalence Rate, 2000–2030
Table 93 ROW: Market Size, By Type, 2012–2019 ($Million)
Table 94 ROW: Traditional Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 95 ROW: Modern Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 96 ROW: Traditional Human Insulin Market Size, By Brand , 2012–2019 ($Million)
Table 97 ROW: Modern Human Insulin Market Size, By Brand, 2012–2019 ($Million)
Table 98 ROW: Traditional Human Insulin Market Size, By Region, 2012-2019 ($Million)
Table 99 ROW: Modern Human Insulin Market Size, By Region, 2012-2019 ($Million)
Table 100 Latin America: Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 101 Middle East: Human Insulin Market Size, By Type, 2012–2019 ($Million)
Table 102 Africa: Market Size, ByType, 2012–2019 ($Million)
Table 103 ROW: Short-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 104 ROW: Intermediate-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 105 ROW: Premixed Traditional Human Insulin Market Size, By Region, 2014–2019 ($Million)
Table 106 ROW: Long-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 107 ROW: Rapid-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 108 ROW: Premixed Modern Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 109 New Product Approvals, 2011–2014
Table 110 Collaborations, Agreements, and Joint Ventures, 2011–2014
Table 111 Other Developments, 2011–2014
Table 103 ROW: Short-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 104 ROW: Intermediate-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 105 ROW: Premixed Traditional Human Insulin Market Size, By Region, 2014–2019 ($Million)
Table 106 ROW: Long-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 107 ROW: Rapid-Acting Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 108 ROW: Premixed Modern Human Insulin Market Size, By Region, 2012–2019 ($Million)
Table 109 New Product Approvals, 2011–2014
Table 110 Collaborations, Agreements, and Joint Ventures, 2011–2014

List of Figures

Figure 1 Research Methodology
Figure 2 Market Size Estimation Model
Figure 3 Market Forecasting Model
Figure 4 Global Market Size, Biologics Vs. Biosimilars, 2014–2019 ($Million)
Figure 5 Global Market, Traditional Human Insulin Vs. Modern Human Insulin, 2014–2019 ($Million)
Figure 6 Global Market Size, By Brand, 2014-2019 ($Million)
Figure 7 Market Overview
Figure 8 Market Snapshot, 2014 ,($Million)
Figure 9 Global Market, By Type of Insulin, 2014 ($Million)
Figure 10 Opportunity Matrix: Global Market, By Brand, 2014
Figure 11 Market, Geographic Analysis, By Type, 2014 ($Million)
Figure 12 Market, By Geography, 2014 & 2019 ($Million)
Figure 13 Human Insulin Timeline
Figure 14 Market Segmentation
Figure 15 Global Market Share Analysis, By Key Player, 2013 ($Million)
Figure 16 North America: Market Share Analysis, By Key Player, 2013 ($Million)
Figure 17 Europe: Market Share Analysis, By Key Player, 2013 ($Million)
Figure 18 Asia-Pacific: Market Share Analysis, By Key Player, 2013 ($Million)
Figure 19 ROW: Market Share Analysis, By Key Player, 2013 ($Million)
Figure 20 Insulin in Pipeline, By Company
Figure 21 Insulin in Pipeline, By Clinical Trial Phases
Figure 22 Insulin in Phase-I Clinical Trials
Figure 23 Insulin in Phase-II Clinical Trials
Figure 24 Insulin in Phase-III Clinical Trials
Figure 25 Insulin in Phase-IV Clinical Trials
Figure 26 Global Traditional Human Insulin Market Share, By Type, 2014
Figure 27 Global Traditional Human Insulin Market Size, By Region,2014 ($Million)
Figure 28 Global Modern Human Insulin Market Size, ByType,2014 Vs. 2019 ($Million)
Figure 29 Global Modern Human Insulin Market Size, By Region, 2014($Million)
Figure 30 Global Traditional Human Insulin Market Size, By Brand, 2014 Vs. 2019 ($Million)
Figure 31 Modern Market Size, By Brand, 2014 Vs. 2019 ($Million)
Figure 32 Major Potential Markets
Figure 33 Opportunity Matrix: Market Size, By Region, 2014
Figure 34 Opportunity Matrix : Global Market, By Country, 2014
Figure 35 Key Growth Strategies of the Global Market, 2011–2014
Figure 36 Geographic Presence (Manufacturing Plants)
Figure 37 Recent Financials, 2011– 2013
Figure 38 Business Revenue Mix
Figure 39 Geographic Revenue Mix
Figure 40 Geographic Presence (Manufacturing Plants)
Figure 41 Insulin in Phase-Iv Clinical Trials
Figure 42 Business Revenue Mix (Human Pharmaceutical Products)
Figure 43 Geographic Revenue Mix
Figure 44 Geographic Presence (Manufacturing Plants)
Figure 45 Recent Financials, 2011– 2013
Figure 46 Business Revenue Mix
Figure 47 Geographic Revenue Mix
Figure 48 Geographic Presence (Manufacturing Plant)
Figure 49 Recent Financials, 2011– 2013
Figure 50 Business Revenue Mix
Figure 51 Geographic Revenue Mix
Figure 52 Geographic Presence (Manufacturing Plant)
Figure 53 Recent Financials, 2011– 2013
Figure 54 Business Revenue Mix
Figure 55 Geographic Revenue Mix

Published By: MarketsandMarkets
Product Code: MarketsandMarkets1941


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: